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INTRODUCTION
Gabapentin is an anticonvulsant that was synthesized as a
structural analog to  -aminobutyric acid (GABA) (1). In-
trathecal or systemic delivery of gabapentin diminishes hyper-
algesia in tissue injury pain models without affecting acute
noxious stimuli threshold (2, 3). Furthermore, the antinoci-
ceptive effect of gabapentin is more powerful after intrathecal
rather than systemic administration (4, 5). These findings
suggest that gabapentin may alter the facilitated state and
the major site of action of gabapentin may be the spinal cord.
Although the mechanisms of action of gabapentin are not
clear, the relations to specific receptors (1, 2) or substances
(6), L-amino acid transporter (7), or voltage-dependent cal-
cium channel (8) has been proposed as the sites of action of
gabapentin. 
Recently, understanding of neurotransmitters and systems
such as serotonergic, adrenergic, cholinergic, and purinergic
receptors involved in nociceptive modulation in the spinal
cord has been increased (9-12). 
The formalin test is an experimental model which shows
acute nociception followed by facilitated state which occurs
secondary to the persistent afferent input generated by a local
tissue injury. 
Thus, the aim of the present study was to observe the effect
of intrathecal gabapentin in the formalin test and to further
evaluate the mechanisms of action of gabapentin at the spinal
level.
MATERIALS AND METHODS
The studies were conducted under a protocol approved by
the Institutional Animal Care Committee, Research Institute
of Medical Science, Chonnam National University. 
Male Sprague-Dawley rats (250-300 g) were used. Rats
were housed in group cages on a 12-h night/day cycle with
access to food and water at all times. For drug administration,
an intrathecal catheter was implanted during enflurane anes-
thesia, as previously described (13).
A polyethylene (PE-10) catheter was advanced caudally
by 8.5 cm through an incision in the atlantooccipital mem-
brane to the lumbar enlargement. The exterior part of the
catheter was tunneled subcutaneously and exited at the top
of head and plugged with a piece of steel wire. The skin was
closed with 3-0 silk sutures. Rats showing neurologic deficits
postoperatively were sacrificed immediately. After surgery,
rats were kept in individual cages and allowed to recover for
4-5 days.
The following drugs were used in this study: gabapentin
(1-[aminomethyl] cyclohexanacetic acid), D-serine (Sigma
Chemical Co., St., Louis, MO, U.S.A.), NMDA (N-methyl-
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Spinal Gabapentin and Antinociception: Mechanisms of Action 
Spinal gabapentin has been known to show the antinociceptive effect. Although sev-
eral assumptions have been suggested, mechanisms of action of gabapentin have
not been clearly established. The present study was undertaken to examine the
action mechanisms of gabapentin at the spinal level. Male SD rats were prepared
for intrathecal catheterization. The effect of gabapentin was assessed in the forma-
lin test. After pretreatment with many classes of drugs, changes of effect of gaba-
pentin were examined. General behaviors were also observed. Intrathecal gaba-
pentin produced a suppression of the phase 2 flinching, but not phase 1 in the for-
malin test. The antinociceptive action of intrathecal gabapentin was reversed by
intrathecal NMDA, AMPA, D-serine, CGS 15943, atropine, and naloxone. No antag-
onism was seen following administration of bicuculline, saclofen, prazosin, yohim-
bine, mecamylamine, L-leucine, dihydroergocristine, or thapsigargin. Taken togeth-
er, intrathecal gabapentin attenuated only the facilitated state. At the spinal level,
NMDA receptor, AMPA receptor, nonstrychnine site of NMDA receptor, adenosine
receptor, muscarinic receptor, and opioid receptor may be involved in the antinoci-
ception of gabapentin, but GABA receptor, L-amino acid transporter, adrenergic
receptor, nicotinic receptor, serotonin receptor, or calcium may not be involved.  
Key Words : Analgesics, Non-Narcotic; Gabapentin; Injections, SpinalD-aspartate, Research Biochemical Internationals [RBI],
Natick, MA, U.S.A.), AMPA (alpha-amino-3-hydroxy-5-
methtyl-4-isoxazolepropionate RBI), L-leucine (Sigma),
bicuculline (Sigma), saclofen (RBI), prazosin hydrochloride
(Sigma), yohimbine hydrochloride (Sigma), atropine sulfate
(RBI), mecamylamine hydrochloride (RBI), CGS 15943
(RBI), naloxone hydrochloride (Sigma), dihydroergocristine
methanesulfonate (RBI), and thapsigargin (RBI). CGS
15943, AMPA, and thapsigargin were dissolved in DMSO.
Yohimbine and dihydroergocristine were dissolved in dis-
tilled water. Saclofen and prazosin were dissolved in 0.1 N
NaOH and methyl alcohol, respectively. Other drugs were
prepared by dissolving them in normal saline. Intrathecal
administration of drugs was performed using a hand-driv-
en, gear-operated syringe pump. All the drugs were deliv-
ered in a volume of 10  L solution, followed by an addition-
al 10  L of normal saline to flush the catheter. 
Pinna reflex, corneal reflex, and motor function were exam-
ined at 5, 10, 20, 30, 40, 50, and 60 min after intrathecal
administration of gabapentin (300  g, n=5). Motor function
was assessed by placing reflex, stepping reflex, and righting
reflex. 
For the nociceptive stimulus, 50  L of 5% formalin solu-
tion was injected subcutaneously into the plantar surface of
the hindpaw using a 30 gauge needle. The formalin injection
produces a characteristic pain behavior, biphasic flinch-
ing/shaking of the injected paw. Such pain behavior was there-
fore quantified by periodically counting the incidences of
spontaneous flinching/shaking of the injected paw. The num-
bers of flinching were counted for 1-min periods at 1 and 5
min and at 5-min intervals from 10 to 60 min. Two phases
of spontaneous flinching were observed after the formalin injec-
tion. Phase 1 and phase 2 were defined as 0-9 and 10-60 min
after formalin injection, respectively. After the observation
period of 1 hr, animals were immediately sacrificed.
Four to five days after surgery, rats were placed in a restraint
cylinder for the experiment. After a 15-20 min adaptation,
rats were then assigned to one of the drug treatment groups.
Control experiments were performed with saline. The rats
were used only once. 
Time course and dose-response of the antinociceptive action
of intrathecal gabapentin (10, 30, 100, 300  g) were deter-
mined. Gabapentin was administered 10 min before forma-
lin injection. 
To determine mechanisms of action of intrathecal gaba-
pentin, many kinds of drugs were intrathecally given 10 min
before the delivery of gabapentin (300  g), and formalin was
injected 10 min later. Doses of drugs for antagonism were
chosen based on the preliminary experiments, which were the
maximal doses without affecting the control formalin re-
sponse. Drugs were as follows: 1) GABA receptor; GABAA
antagonist, bicuculline 0.3  g, GABAB antagonist, saclofen
30  g, 2) NMDA receptor; NMDA 0.1  g, 3) AMPA recep-
tor; AMPA 0.003  g, 4) nonstrychnine site agonist of NMDA
receptor; D-serine 100  g, 5) L-amino acid transporter com-
petitor; L-leucine 100  g, 6) opioid receptor; opioid antago-
nist, naloxone 0.3  g, 7) adrenergic receptor; alpha-1 antag-
onist prazosin 3  g, alpha-2 antagonist, yohimbine 10  g,
8) cholinergic receptor; muscarinic antagonist, atropine 10
g, nicotinic antagonist, mecamylamine 10  g, 9) serotonin
receptor; serotonin antagonist, dihydroergocristine 3  g, 10)
adenosine receptor; adenosine antagonist CGS 15943 0.03
g, and 11) calcium uptake inhibitor; thapsigargin 0.3  g.
Data are expressed as mean±SEM. The time response data
are presented as the number of flinching. The dose-response
data are presented as the percentage maximal possible in-
hibitory effect (%MPIE) in each phase. 
The numbers of flinching were converted to %MPIE accor-
ding to the following formula.
Sum of phase 1(2) count with drug %MPIE =                                                                  ×100 
Sum of phase 1(2) count in control group
Dose-response data were analyzed by one-way analysis of
variance (ANOVA) with Scheffe for post hoc. 
Comparison of antagonism for the effect of gabapentin was
analyzed by unpaired t-test. p<0.05 was considered statisti-
cally significant.
RESULTS
Neither change of pinna reflex and corneal reflex nor motor
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Fig. 1. Time course effect of gabapentin in the formalin test.
Gabapentin was intrathecally administared 10 min prior to injec-
tion of formalin into the hindpaw. Data are presented as the
number of flinching. Each point on the graph represents mean
±SEM of 7-8 rats. 
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impairment was noted after intrathecal administration of
gabapentin. Gabapentin caused a decreased spontaneous
activity and urination in some rats. Other abnormal behav-
iors were not observed. Subcutaneous injection of formalin
into the hindpaw resulted in a biphasic flinching response
of the injected paw. Fig. 1 shows the time course of the
effect of intrathecal gabapentin, administered 10 min before
formalin injection, in the formalin test. Intrathecal gabapentin
did not alter the flinching response during phase 1. During
phase 2, gabapentin produced a dose-dependent suppression
of the flinching response (Fig. 2). 
The antinociceptive effects of intrathecal gabapentin were
antagonized by intrathecal NMDA, AMPA, D-serine (Fig.
3), CGS 15943, atropine, and naloxone (Fig. 4), whereas bicu-
culline, saclofen (Fig. 5), prazosin, yohimbine, mecamylamine
(Fig. 6), L-leucine, dihydroergocristine, and thapsigargin
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Fig. 2. Dose response effect of gabapentin in the formalin test. Data are presented as the percentage maximal possible inhibitory effect
(%MPIE). Intrathecal gabapentin dose-dependently suppresses only phase 2 flinching response. Each point on the graph represents
mean±SEM of 7-8 rats. C: control, *p<0.001 compared with control.
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Fig. 3. The effect of NMDA, AMPA, and D-serine on the antinociception of gabapentin (GP, 300 g) during phase 2 of the formalin test.
NMDA, AMPA, and D-serine were intrathecally administered 20 min prior to the injection of formalin. Intrathecal GP was given 10 min
before formalin injection. Data are presented as the number of flinching or the percentage maximal possible inhibitory effect (%MPIE).
NMDA, AMPA, and D-serine alone do not affect the control response (A), but all of them reversed the effect of GP (B). Each treatment
group represents mean±SEM of 5-6 rats. *p<0.05, compared with GP.
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A B(Fig. 7) did not reverse the antinociception of gabapentin. 
DISCUSSION
In these experiments, intrathecal gabapentin did not affect
the flinching response of phase 1 in the formalin test, but it
decreased the phase 2 response. The results of gabapentin
observed in this study were consistent with the previous find-
ings (2, 14). Therefore, these observations uphold that spinal
gabapentin may alter the facilitated state evoked by persis-
tent afferent input without effects on acute nociception. 
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Fig. 4. The effect of CGS 15943, atropine, and naloxone on the antinociception of gabapentin (GP, 300  g) during phase 2 of the forma-
lin test. CGS 15943, atropine, and naloxone were intrathecally administered 20 min prior to the injection of formalin. Intrathecal GP was
given 10 min before formalin injection. Data are presented as the number of flinching or the percentage maximal possible inhibitory effect
(%MPIE). CGS 15943, atropine, and naloxone alone do not affect the control response (A), but all of them reverse the effect of GP (B).
Each treatment group represents mean±SEM of 5-6 rats. *p<0.05, compared with GP.
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Fig. 5. The effect of bicuculline and saclofen on the antinociception of gabapentin (GP, 300  g) during phase 2 of the formalin test. Bicu-
culline and saclofen were intrathecally administered 20 min prior to injection of formalin. Intrathecal GP was given 10 min before formalin
injection. Data are presented as the number of flinching or the percentage maximal possible inhibitory effect (%MPIE). Bicuculline and
saclofen alone alone do not affect the control response (A), but neither bicuculline nor saclofen reverse the effect of GP (B). Each treat-
ment group represents mean±SEM of 5-6 rats. 
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Although the antinociceptive mechanisms of spinal gaba-
pentin remain unclear, several hypotheses have been suggest-
ed. It has been reported that gabapentin decreases glutamate
concentrations and inhibits the release of glutamate and glu-
tamatergic synaptic transmission presynatically (15-17). Glu-
tamate acts on the NMDA receptor and non-NMDA recep-
tor and shows the excitatory effect (18, 19). Further, AMPA-
evoked neuronal response is inhibited by gabapentin (20, 21).
These findings suggest that NMDA or AMPA receptor may
be an action site of gabapentin. Our results that NMDA or
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Fig. 6. The effect of prazosin, yohimbine, and mecamylamine on the antinociception of gabapentin (GP, 300  g) during phase 2 of the
formalin test. Prazosin, yohimbine, and mecamylamine were intrathecally administered 20 min prior to the injection of formalin. Intrathecal
GP was given 10 min before formalin injection. Data are presented as the number of flinching or the percentage maximal possible
inhibitory effect (%MPIE). Prazosin, yohimbine, and mecamylamine alone do not affect the control response (A), but none of them
reverse the effect of GP (B). Each treatment group represents mean±SEM of 5-6 rats.
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Fig. 7. The effect of L-leucine, dihydroergocristine (HEC), and thapsigargin on the antinociception of gabapentin (GP, 300  g) during
phase 2 of the formalin test. L-leucine, HEC, and thapsigargin were intrathecally administered 20 min prior to the injection of formalin.
Intrathecal GP was given 10 min before formalin injection. Data are presented as the number of flinching or the percentage maximal pos-
sible inhibitory effect (%MPIE). L-leucine, HEC, and thapsigargin alone do not affect the control response (A), but none of them reverse
the effect of GP (B). Each treatment group represents mean±SEM of 5-6 rats.
Time (min)
%
 
M
P
I
E
100
80
60
40
20
0
Control GP L-leucine HEC Thapsigargin
+++
GP GP GP
●
▼
Control
L-leucine
HEC
Thapsigargin
●
●
●
●
●
●●
●
●
●
●●
●
▼
▼▼
▼
▼
▼
▼ ▼
▼
▼
▼
▼
▼
M
e
a
n
 
f
l
i
n
c
h
e
s
/
m
i
n
GP GP GP
A B
A BAMPA attenuated the antinociceptive effect of gabapentin
support these observations. Additionally, an agonist at the
nonstrychnine site of NMDA receptor complex reversed the
antinociception of gabapentin. This observation is also con-
sistent with others (2, 22). Therefore, NMDA receptor, AMPA
receptor, and the nonstrychnine site of NMDA receptor may
be action sites of gabapentin. Previous studies have shown
that gabapentin increases the concentration, the rate of syn-
thesis, and the release of GABA (1, 6). However, intrathecal
administration of GABAA or GABAB receptor antagonists
did not reverse the antiallodynic effects produced by gaba-
pentin (23). In the current study, the antinociceptive action
of gabapentin was not affected by either GABAA or GABAB
receptor antagonists. Thus, it could be supposed that spinal
GABA receptors may not be directly involved in the antinoci-
ceptive effect of intrathecal gabapentin. It has been proposed
that gabapentin crosses several membrane barriers in the body
via a specific amino acid transporter and competes with le-
ucine, isoleucine, valine, and phenylalanine for transport (1,
7). However, intrathecal L-leucine and BCH did not antag-
onize the antiallodynic effect of intrathecal gabapentin (24).
Hence, gabapentin may not have to enter nerve terminal or
cells via L-amino acid transporter, which was supported by
our results. 
The  2 subunit of voltage-sensitive calcium channels has
been suggested as the binding site of gabapentin (8). Howev-
er, electrophysiological studies did not exhibit an action of
gabapentin on voltage-sensitive calcium channels (25).
Although we did not investigate the role of calcium chan-
nels for the antinociception of gabapentin, it may not inhib-
it the calcium uptake. Gabapentin augments the level of
serotonin (26) and intrathecal serotonin produces an antino-
ciceptive effect being mediated through serotonin receptors
(9). Our study showed that the antinociceptive effect of
gabapentin was not reduced by serotonin antagonist. Hence,
the serotinin receptor does not seem to be involved in the
effect of gabapentin. Spinal adrenergic receptors and cholin-
ergic receptors are active to modulate the nociceptive infor-
mation (10, 11). In this study, the effect of gabapentin against
nociception was not diminished by neither adrenergic antag-
onists nor nicotinic antagonist, while it was reduced by mus-
carinic antagonist. Accordingly, it may be conceivable that
the antinociception of gabapentin is mediated by muscarinic
receptor. Interestingly, naloxone reversed the effect of gaba-
pentin, which implicates that there are certain connections
between the effect of gabapentin and opioid receptors. 
Adenosine is an endogenous purine compound with vari-
ous effects on the modulation of nociceptive information at
the spinal level (27). The antinociception of intrathecal adeno-
sine is mediated through adenosine receptors in dorsal horn
of the spinal cord (12). Both A1 and A2 subtypes of adeno-
sine receptors have been identified in the substantia gelati-
nosa of the dorsal horn (28). Considering that the antinoci-
ceptive effect of gabapentin was reversed by adenosine antag-
onist in the present study, it could be supposed that gaba-
pentin may act on the adenosine receptors in the spinal cord.
In addition, intrathecal gabapentin is more potent than
systemic injection in terms of antinociception (5, 6), empha-
sizing that the spinal cord may be a major action site. The
above-mentioned findings jointly suggest that gabapentin
may act on a certain site or receptors at the spinal level and
produce the antinociceptive effect.
In conclusion, spinal gabapentin exhibits antinociception
in the facilitated state. These antinociceptive effects may be
mediated through spinal NMDA receptor, AMPA receptor,
nonstrychnine site of NMDA receptor, adenosine receptors,
and muscarinic receptor.  
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